Milton J Finegold1. 1. Department of Pathology, Texas Children's Hospital, Houston, Texas 77030, USA. finegold@bcm.tmc.edu
Abstract
BACKGROUND: US and European practices differ with respect to treating hepatoblastoma (HB). Should chemotherapy be given prior to resection in all cases, and even without biopsy confirmation (SIOPEL)? PROCEDURE AND RESULTS: US data indicate that 40% of HBs are primarily resectable with no operative mortality and that those with pure fetal histology and low mitotic rate do not require toxic chemotherapy. They also suggest that those with a significant fraction of small undifferentiated cells do not respond to otherwise effective chemotherapy. Both US and European studies report a significant error rate in the clinical and imaging diagnosis of HB. CONCLUSIONS: Although only 6.5% of confirmed HBs fall into categories that would be managed differently by US standards, there is no justification for denying those patients a more appropriate treatment nor should the 6-10% of cases that are misdiagnosed as HB be treated incorrectly. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND: US and European practices differ with respect to treating hepatoblastoma (HB). Should chemotherapy be given prior to resection in all cases, and even without biopsy confirmation (SIOPEL)? PROCEDURE AND RESULTS: US data indicate that 40% of HBs are primarily resectable with no operative mortality and that those with pure fetal histology and low mitotic rate do not require toxic chemotherapy. They also suggest that those with a significant fraction of small undifferentiated cells do not respond to otherwise effective chemotherapy. Both US and European studies report a significant error rate in the clinical and imaging diagnosis of HB. CONCLUSIONS: Although only 6.5% of confirmed HBs fall into categories that would be managed differently by US standards, there is no justification for denying those patients a more appropriate treatment nor should the 6-10% of cases that are misdiagnosed as HB be treated incorrectly. Copyright 2002 Wiley-Liss, Inc.
Authors: Marcio H Malogolowkin; Howard M Katzenstein; Rebecka L Meyers; Mark D Krailo; Jon M Rowland; Joel Haas; Milton J Finegold Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: E Hiyama; H Yamaoka; T Matsunaga; Y Hayashi; H Ando; S Suita; H Horie; M Kaneko; F Sasaki; K Hashizume; A Nakagawara; N Ohnuma; T Yokoyama Journal: Br J Cancer Date: 2004-08-31 Impact factor: 7.640